SBIR/STTR Research Award

SERODIAGNOSIS OF ULCER

Award identifier 5b294ff185390821d0c371a55e5bdc3b346066c69cd6110dc0786d8284a25769Awarding agency Department of Health and Human Services

Award amount

$50,000

Program and phase

SBIR · Phase I

Award year

1988

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
Allergy Immuno Technologies
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

SEVERAL SPECIES OF CAMPYLOBACTER ARE KNOWN TO BE ASSOCIATED WITH WIDE RANGE OF HUMAN AND ANIMAL ILLNESSES, MAINLY GASTROENTERITIS, COLITIS, SEPSIS AND URINARY TRACT INFECTIONS. RECENTLY MANY STUDIES CONFIRMED THE CORRELATIONBETWEEN THE PRESENCE OF C. PYLORIDIS (C. PYLORI) ON THE GASTRIC MUCOSA AND DUODENAL ULCERATION. THE MECHANISM BY WHICH THIS ORGANISM INDUCES ULCER IS NOT CLEAR YET BUT IT IS KNOWN THAT COLONIZATION OF C. PYLORIDIS INDUCES LOCAL AND SYSTEMIC IMMUNE RESPONSES. THIS ANTIBODY RESPONSE DIRECTLY CORRELATES WITH HISTOLOGICAL DIAGNOSIS OF CHRONIC OR ACTIVE ULCERS AS WELL AS RENAL TRANSPLANT PATIENTS. THEREFORE, DETECTION OF SPECIFIC ANTIBODIES (IGA, IGG, IGM) AGAINST THIS BACTERIA IS A GOOD INDICATION OF DIAGNOSIS OF GASTRIC ULCER. DURING PHASE I OF THIS STUDY FOUR DIFFERENT ANTIGERS FROM C. PYLORIDIS, C. JEJUNI AND C. COLI WILL BE PREPARED. THESEANTIGENS WILL BE USED FOR DEVELOPMENT OF ELISA AND MEASUREMENT OF ANTIBODIES IN THE PATIENT'S SERA WITH CONFIRMED MEDICAL HISTORY OF ULCER. CROSS REACTIVITY AND SPECIFICITY OF THESE ANTIBODIES WILL BE EXAMINED WITH ANTIGENS OF THREE DIFFERENT SPECIES OF CAMPYLOBECTER (C. FETUS, C. JEJUNI, C. COLI) KNOWN AS A MAJOR CAUSE OF GASTROENTERITIS BUT NOT OF GASTRIC ULCER. ALL ANTIGENS WILLBE ANALYZED BY ELECTROPHORESIS AND SPECIFIC BONDS WILL BE IDENTIFIED BY WESTERN BLOTTING USING POSITIVE C. PYLORIDIS SERA. DURING PHASE II OF THIS STUDY, SPECIES-SPECIFIC ANTIGEN(S) WILL BE PURIFIED AND CHARACTERIZED. MONOCLONAL ANTIBODIES WILL BE PRODUCED FOR HISTOLOGICAL EXAMINATIONS AS WELL AS FOR AFFINITY PURIFICATION OF THESE SPECIFIC ANTIGENS AND THEIR USE IN THE DEVELOPMENT OF SPECIFIC ELISA KITS. FINALLY, AFTER PHASE I FEASIBILITY STUDIES AND PHASE II OF SPECIFIC ELISA KIT PRODUCTION, WE HOPE THAT OUR ELISA TEST WILL REPLACE THE DIFFICULT AND EXPENSIVE PROCEDURES SUCH AS UPPER GASTROINTESTINAL ENDOSCOPY AND BIOPSY, WHICH ARE PRESENTLY REQUIRED TO DEMONSTRATE THE PRESENCE OF C. PYLORIDIS IN THE STOMACH.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.